Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039455 · ClinicalTrials.gov registry record · Phase 1
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00039455: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00039455 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039455, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with flavopiridol may kill more tumor cells. Phase I trial to study the effectiveness of combining trastuzumab with flavopiridol in treating patients who have metastatic breast cancer
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- BIOLOGICAL trastuzumab
- DRUG alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039455
The ClinicalTrials.gov registry entry for NCT00039455 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00039455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039455 about?
NCT00039455 is a clinical study titled "Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer". Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with flav...
What is the current status of trial NCT00039455?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2002-04.
What interventions are being tested in trial NCT00039455?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), trastuzumab (BIOLOGICAL), alvocidib (DRUG).
Who is sponsoring clinical trial NCT00039455?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.